Skip to main content

Table 3 Risk factors for ipsi-LLNM in patients with PTC

From: Prediction of ipsilateral lateral cervical lymph node metastasis in papillary thyroid carcinoma: a combined dual-energy CT and thyroid function indicators study

 

Univariate analysis

Multivariate analysis

OR

95% CI

P value

OR

95% CI

P value

Sex

0.690

0.418–1.139

.147

   

Age

0.726

0.454–1.160

.180

   

Tg (ng/mL)

2.832

1.837–4.365

.000

2.668

1.590–4.475

.000

Anti-Tg (IU/mL)

2.121

1.386–3.245

.001

2.001

1.202–3.333

.008

Anti-TPO (IU/mL)

1.054

0.693–1.603

.805

   

HT

0.738

0.430–1.267

.271

   

Nodular goiter

1.018

0.649–1.594

.940

   

Volume (cm3)

1.093

1.029–1.161

.004

   

Cystic degeneration

1.816

1.190–2.771

.006

   

Calcification

1.989

1.298–3.048

.002

   

IC IAP (mg/mL)

4.418

2.787–7.004

.000

3.691

2.170–6.278

.000

IC IVP (mg/mL)

2.517

1.640–3.863

.000

2.122

1.271–3.541

.004

ETE

6.350

4.012–10.050

.000

6.335

3.768–10.651

.000

  1. LLNM Lateral lymph node metastasis, PTC Papillary thyroid carcinoma, OR Odds ratio, CI Confidence interval, HT Hashimoto’s thyroiditis, ETE Extrathyroidal extension, IC Iodine concentration, IAP In the arterial phase, IVP In the venous phase
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us